Engineered Microbes Comprising Tumor Neoantigen Vectors for Cancer Immunotherapy
AssigneeThe Trustees of Columbia University in the City of New York
InventorsAndrew REDENTI, Tal DANINO, Jongwon IM, Nicholas ARPAIA
Life of this patent
Estimating the term…
Abstract
Engineered Escherichia coli Nissle bacteria comprising one or more heterologous nucleic acids that encode one or more neoantigen epitopes derived from antigenic epitopes present on the surface of a tumor cell and related compositions and methods.
Claims15
An engineered Escherichia coli Nissle bacteria comprising one or more heterologous nucleic acids that encode one or more neoantigen epitopes present on the surface of a tumor cell.
A method of fabricating a personalized vaccine for a subject with cancer, comprising:
- (a) optionally obtaining a biological sample from the subject, wherein the biological sample comprises one or more nucleic acids derived from a cancer cell present in the subject;
- (b) identifying one or more potential neoantigens from the one or more nucleic acids by comparing nucleic acid sequences of the one or more nucleic acids to nucleic acid sequences from a non-cancerous cell of the same type;
- (c) optionally screening peptides comprising the one or more potential neoantigens for an immunogenic response;
- (d) optionally identifying one or more epitopes on one or more neoantigens that produced an immunogenic response;
- and (e) transforming a Escherichia coli Nissle bacteria with one or more vectors comprising one or more heterologous nucleic acids that encode one or more neoantigen epitopes, producing the personalized vaccine thereby.
A method of treating a subject with cancer with a personalized vaccine, comprising:
- (a) optionally obtaining a biological sample from the subject, wherein the biological sample comprises one or more nucleic acids derived from a cancer cell present in the subject;
- (b) identifying one or more potential neoantigens from the one or more nucleic acids by comparing nucleic acid sequences of the one or more nucleic acids to nucleic acid sequences in a non-cancerous cell of the same type;
- (c) optionally screening peptides comprising the one or more potential neoantigens for an immunogenic response;
- (d) optionally identifying one or more epitopes on one or more neoantigens that produced an immunogenic response;
- (e) transforming a Escherichia coli Nissle bacteria with one or more vectors comprising one or more heterologous nucleic acids that encode one or more neoantigen epitopes, producing a personalized vaccine thereby;
- and (f) administering the personalized vaccine to the subject.
Dependencies are inferred from the claim text.